Masimo (NASDAQ:MASI) Issues FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 4.900-5.100 for the period, compared to the consensus EPS estimate of 4.670. The company issued revenue guidance of -. Masimo also updated its FY 2024 guidance to 4.100-4.100 EPS.

Masimo Price Performance

Masimo stock opened at $172.29 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo has a 52-week low of $101.61 and a 52-week high of $180.97. The firm’s fifty day moving average is $169.23 and its 200 day moving average is $140.13. The company has a market cap of $9.22 billion, a price-to-earnings ratio of 118.82 and a beta of 1.01.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.63 EPS. Sell-side analysts forecast that Masimo will post 4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MASI has been the subject of several research reports. BTIG Research boosted their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company upped their price objective on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Piper Sandler increased their target price on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Finally, Raymond James boosted their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $179.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.